在细胞学不确定的甲状腺结节中,互依成对微小RNA表达分析与突变面板诊断性能的回顾性评估
该研究在178例Bethesda III/IV细胞学不确定甲状腺结节样本中,回顾性比较MPTXv1与加入成对miRNA表达分析的MPTXv2的诊断性能。MPTXv2使ROC AUC从0.85升至0.97,阳性阈值下诊断准确率从83%升至93%,特异度从90%升至98%,中度风险组从50例(28%)降至24例(13%)。作者认为需前瞻性试验在临床实践中确认。
要点
- MPTXv2较MPTXv1显著提高诊断准确率(83%→93%)和特异度(90%→98%)。
- MPTXv2使中度风险组样本从50例(28%)降至24例(13%),降幅52%。
- 作者指出需前瞻性试验在临床实践环境中确认这些发现。
核心结论
- 与MPTXv1相比,采用成对miRNA表达分析的MPTXv2显著改善了细胞学不确定甲状腺结节风险分层的诊断准确率,并缩小了中度风险组的规模。
- 作者指出需前瞻性试验在临床实践环境中确认这些发现。
研究设计与样本
- 训练队列为组织病理学证实的良性结节(n=50),用于定义11种miRNA成对表达分析的均值和标准差并构建良性/恶性分析器(MPTXv2)。
- 临床验证使用来自多中心、盲法回顾性研究的178例细胞学不确定甲状腺结节(Bethesda III和IV)样本,这些样本此前已用MPTXv1评估。
主要发现
- MPTXv2较MPTXv1显著改善检测性能:ROC曲线下面积(AUC)从0.85增至0.97(p < 0.001)。
- 阳性阈值下诊断准确率从83%[95%CI=76-88]显著提高至93%[95%CI=89-96](p < 0.05)。
- 阳性阈值下特异度MPTXv1为90%[95%CI=84-95],MPTXv2改善至98%[95%CI=94-99]。
- 使用MPTXv2后,中度风险队列从50例样本(队列的28%)降至24例样本(队列的13%),这一52%的下降具有统计学显著性(p < 0.001)且具有临床意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需前瞻性试验在临床实践环境中确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The addition of genetic analysis to the evaluation of thyroid nodule fine-needle aspiration biopsy samples improves diagnostic accuracy of cytologically indeterminate thyroid nodules (ITNs) with Bethesda III or IV cytopathology. We previously reported the performance of a multiplatform molecular test, referred to in this study as MPTXv1, that includes a mutation panel (ThyGeNEXT®) plus an algorithmic microRNA (miRNA) risk classifier (ThyraMIR®). Complex interactions of growth-promoting and -suppressing miRNAs affect the phenotype. We previously demonstrated that accounting for these interactions with pairwise miRNA expression analysis improves the diagnosis of medullary thyroid carcinoma. In this study, we assess the impact of pairwise miRNA expression analysis on risk stratification of ITNs. Methods: Pairwise expression analysis of 11 miRNAs was performed on a training cohort of histopathology-proven benign nodules (n = 50) to define the mean and standard deviation of each pairwise analysis and create a Benign/Malignant Profiler (MPTXv2), deviations from which predicted the malignancy risk. Clinical validation of MPTXv2 was assessed using a cohort of 178 ITN (Bethesda III and IV) samples from a multicentered, blinded retrospective study, previously evaluated by MPTXv1. Results: Compared with MPTXv1, MPTXv2 significantly improved the test performance. The receiver operating characteristic (ROC) areas under the curve (AUC) increased from 0.85 to 0.97 (p < 0.001), and the diagnostic accuracy at the positive threshold increased significantly (p < 0.05) from 83% [95% confidence interval (CI) = 76-88] to 93% [CI = 89-96]. The significant improvement in the ROC AUC and the diagnostic accuracy was due to a strong statistical trend for improvement in specificity at the positive threshold. At the positive threshold, the specificity for MPTXv1 was 90% [CI = 84-95] and improved to 98% [CI = 94-99] for MPTXv2. Using the MPTXv2, the Moderate-Risk cohort decreased from 50 samples (28% of the cohort) to 24 samples (13% of the cohort). This 52% decrease is statistically significant (p < 0.001) and clinically meaningful. Conclusion: As compared with MPTXv1, pairwise miRNA expression analysis used in MPTXv2 significantly improved the diagnostic accuracy of ITN risk stratification and reduced the size of the Moderate-Risk group. Prospective trials are indicated to confirm these findings in a clinical practice setting.
引用
- Finkelstein SD, Sistrunk JW, Malchoff C, et al. A Retrospective Evaluation of the Diagnostic Performance of an Interdependent Pairwise MicroRNA Expression Analysis with a Mutation Panel in Indeterminate Thyroid Nodules. Thyroid. 2022. PMID: 35943886. doi:10.1089/thy.2022.0124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。